GLPG4059 / Lakefront Biotherapeutics - LARVOL DELTA

A Study in Healthy Male Volunteers Investigating the Safety, Absorption and Elimination of Single Doses of GLPG4059 (clinicaltrials.gov) - P1; N=32; Terminated; Sponsor: Galapagos NV; N=57 ➔ 32; Recruiting ➔ Terminated; Development of compound has been stopped

Clinical • Enrollment change • Trial termination